Tvardi Therapeutics (NASDAQ:TVRD) Issues Earnings Results

Tvardi Therapeutics (NASDAQ:TVRD) announced its quarterly earnings data on Friday. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08), FiscalAI reports.

Tvardi Therapeutics Price Performance

Shares of Tvardi Therapeutics stock opened at $4.18 on Friday. Tvardi Therapeutics has a 1 year low of $2.75 and a 1 year high of $43.65. The company has a market capitalization of $39.21 million, a P/E ratio of -1.35 and a beta of 0.30. The business has a 50 day moving average price of $3.44 and a 200 day moving average price of $3.94.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TVRD. Geode Capital Management LLC acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $2,617,000. JPMorgan Chase & Co. acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $39,000. New York State Common Retirement Fund acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $92,000. Marshall Wace LLP acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $583,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Tvardi Therapeutics in the 2nd quarter valued at $43,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 4th. Finally, BTIG Research reiterated a “buy” rating and set a $15.00 price target on shares of Tvardi Therapeutics in a research report on Wednesday, April 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $55.50.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.